Browsed by
Tag: life sciences

Longevity Industry Systematized for First Time – Press Release by Biogerontology Research Foundation

Longevity Industry Systematized for First Time – Press Release by Biogerontology Research Foundation

Biogerontology Research Foundation


CREDIT: The Biogerontology Research Foundation, Deep Knowledge Life Sciences, Aging Analytics Agency and Longevity.International platform

Editor’s Note: Below is a press release by the Biogerontology Research Foundation on the longevity industry, which has been systematized for the first time in the report entitled The Science of Longevity. This press release was originally published here.

~ Dinorah Delfin, Director of  Recruitment, U.S. Transhumanist Party, February 5, 2018

Friday, Feb. 2, 2017, London, UK: The Biogerontology Research Foundation has embarked on a year-long mission to summarise in a single document the various emerging technologies and industries which can be brought to bear on aging, healthy longevity, and everything in between, as part of a joint project between The Global Longevity Consortium, consisting of the Biogerontology Research FoundationDeep Knowledge Life SciencesAging Analytics Agency and Longevity.International platform.

For scientists, policy makers, regulators, government officials, investors and other stakeholders, a consensus understanding of the field of human longevity remains fragmented, and has yet to be systematized by any coherent framework, and has not yet been the subject of a comprehensive report profiling the field and industry as a whole by any analytical agency to date. The consortium behind this series of reports hope that they will come to be used as a sort of Encyclopedia Britannica and specialized Wikipedia of the emerging longevity industry, with the aim of serving as the foundation upon which the first global framework of the industry will be built, given the significant industry growth projected over the coming years.

Experts on the subject of human longevity, who tend arrive at the subject from disparate fields, have failed even to agree on a likely order of magnitude for future human lifespan. Those who foresee a 100-year average in the near future are considered extreme optimists by some, while others have even mooted the possibility of indefinite life extension through comprehensive repair and maintenance. As such the longevity industry has often defied real understanding and has proved a complex and abstract topic in the minds of many, investors and governments in particular.

The first of these landmark reports, entitled ‘The Science of Longevity‘, standing at almost 800 pages in length, seeks to rectify this.

Part 1 of the report ties together the progress threads of the constituent industries into a coherent narrative, mapping the intersection of biomedical gerontology, regenerative medicine, precision medicine, artificial intelligence, offering a brief history and snapshot of each. Part 2 lists and individually profiles 650 longevity-focused entities, including research hubs, non-profit organizations, leading scientists, conferences, databases, books and journals. Infographics are used to illustrate where research institutions stand in relation to each other with regard to their disruptive potential: companies and institutions specialising in palliative technologies are placed at the periphery of circular diagrams, whereas those involved with more comprehensive, preventative interventions, such as rejuvenation biotechnologies and gene therapies, are depicted as central.

In this report great care was taken to visualize the complex and interconnected landscape of this field via state of the art infographics so as to distill the many players, scientific subsectors and technologies within the field of geroscience into common understanding. Their hope was to create a comprehensive yet readily-understandable view of the entire field and its many players, to serve a similar function that Mendeleev’s periodic table did for the field of chemistry. While these are static infographics in the reports, their creators plan to create complimentary online versions that are interactive and filterable, and to convene a series of experts to analyze these infographics and continually update them as the geroscience landscapes shifts. Similar strategies are employed in Volume II to illustrate the many companies and investors within the longevity industry.

These reports currently profile the top 100 entities in each of the categories, but in producing them, analysts found that the majority of these categories have significantly more than 100 entities associated with them. One of their main conclusions upon finishing the report is that the longevity industry is indeed of substantial size, with many industry and academic players, but that it remains relatively fragmented, lacking a sufficient degree of inter-organization collaboration and industry-academic partnerships. The group plans to expand these lists in follow-up volumes so as to give a more comprehensive overview of the individual companies, investors, books, journals, conferences and scientists that serve as the foundation of this emerging industry.

Since these reports are being spearheaded by the UK’s oldest biomedical charity focused on healthspan extension, the Biogerontology Research Foundation is publishing them online, freely available to the public. While the main focus of this series of reports is an analytical report on the emerging longevity industry, the reports still delve deeply into the science of longevity, and Volume I is dedicated exclusively to an overview of the history, present and future state of ageing research from a scientific perspective.

The consortium of organizations behind these reports anticipate them to be the first comprehensive analytical report on the emerging longevity industry to date, and hope to increase awareness and interest from investors, scientists, medical personnel, regulators, policy makers, government officials and the public-at-large in both the longevity industry as well as geroscience proper by providing a report that simultaneously distills the complex network of knowledge underlying the industry and field into easily and intuitively comprehensible infographics, while at the same time providing a comprehensive backbone of chapters and profiles on the various companies, investors, organizations, labs, institutions, books, journals and conferences for those inclined for a deeper dive into the vast foundation of the longevity industry and the field of geroscience.

It is hoped that this report will assist others in visualising the present longevity landscape and elucidate the various industry players and components. Volume 2, The Business of Longevity, which at approximately 500 pages in length aims to be as comprehensive as Volume 1, is set to be published shortly thereafter, and will focus on the companies and investors working in the field of precision preventive medicine with a focus on healthy longevity, which will be necessary in growing the industry fast enough to avert the impending crisis of global aging demographics.

These reports will be followed up throughout the coming year with Volume 3 (“Special Case Studies”), featuring 10 special case studies on specific longevity industry sectors, such as cell therapies, gene therapies, AI for biomarkers of aging, and more, Volume 4 (“Novel Longevity Financial System”), profiling how various corporations, pension funds, investment funds and governments will cooperate within the next decade to avoid the crisis of demographic aging, and Volume 5 (“Region Case Studies”), profiling the longevity industry in specific geographic regions.

These reports are, however, only the beginning, and ultimately will serve as a launching pad for an even more ambitious project: Longevity.International, an online platform that will house these reports, and also serve as a virtual ecosystem for uniting and incentivizing the many fragmented stakeholders of the longevity industry, including scientists, entrepreneurs, investors, policy makers, regulators and government officials to unite in the common goal of healthspan extension and aversion of the looping demographic aging and Silver Tsunami crisis. The platform will use knowledge crowdsourcing of top tier experts to unite scientists with entrepreneurs, entrepreneurs to investors, and investors to policy-makers and regulators, where all stakeholders can aggregate and integrate intelligence and expertise from each other using modern IT technologies for these types of knowledge platforms, and all stakeholders can be rewarded for their services.


The consortium behind these reports is interested in collaboration with interested contributors, institutional partners, and scientific reviewers to assist with the ongoing production of these reports, to enhance their outreach capabilities and ultimately to enhance the overall impact of these reports upon the scientific and business communities operating within the longevity industry, and can be reached at


About the Biogerontology Research Foundation:

The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.


Bioquark, Inc., and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement – Press Release by Ira Pastor

Bioquark, Inc., and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement – Press Release by Ira Pastor


Ira Pastor

Bioquark, Inc., and Lakmus LLC, announce a multi-disciplinary research collaboration to study age-reversal / longevity-enhancing bio-pharmaceutical development with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, and the Pavlov Institute of Physiology of the Russian Academy of Sciences.

Bioquark, Inc., ( a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow-based Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (, and the Pavlov Institute of Physiology of the Russian Academy of Sciences (, to jointly study the pharmacotherapeutic longevity-enhancement properties of its combinatorial regenerative biologic candidates.

“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.

“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e., gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease, and degeneration.”

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

Read about Mr. Ira S. Pastor here.